Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
EIK1001
i
Other names:
EIK1001, BDB001, BDB 001
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Eikon Therap, Seven and Eight BioPharma
Drug class:
TLR8 agonist, TLR7 agonist, TLR agonist
Related drugs:
‹
imiquimod (4)
SBT6050 (4)
BDC-1001 (2)
BDC-2034 (1)
SBT6290 (1)
VTX 2337 (1)
BDB018 (0)
CV8102 (0)
GQ1007 (0)
NKTR-262 (0)
imiquimod intravesical (0)
ZG0895 (0)
STM-416 (0)
TransCon TLR7/8 Agonist (0)
MEDI9197 (0)
AL-034 (0)
APR003 (0)
BNT411 (0)
LHC165 (0)
MBS8 (0)
RG6115 (0)
DSP-0509 (0)
DPV-001 (0)
IDC-G305 (0)
ATP128 (0)
ONT-10 (0)
imiquimod (4)
SBT6050 (4)
BDC-1001 (2)
BDC-2034 (1)
SBT6290 (1)
VTX 2337 (1)
BDB018 (0)
CV8102 (0)
GQ1007 (0)
NKTR-262 (0)
imiquimod intravesical (0)
ZG0895 (0)
STM-416 (0)
TransCon TLR7/8 Agonist (0)
MEDI9197 (0)
AL-034 (0)
APR003 (0)
BNT411 (0)
LHC165 (0)
MBS8 (0)
RG6115 (0)
DSP-0509 (0)
DPV-001 (0)
IDC-G305 (0)
ATP128 (0)
ONT-10 (0)
›
Associations
News
Trials
Filter by
Latest
1d
A Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001-006 in Combination With Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Patients With Advanced Melanoma (clinicaltrials.gov)
P2/3, N=740, Not yet recruiting, Eikon Therapeutics
1 day ago
New P2/3 trial • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • EIK1001
7ms
BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab (clinicaltrials.gov)
P1, N=50, Active, not recruiting, Eikon Therapeutics | Trial primary completion date: Mar 2024 --> Aug 2024 | Trial completion date: Mar 2024 --> Aug 2024
7 months ago
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • EIK1001
7ms
BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab (clinicaltrials.gov)
P1, N=40, Active, not recruiting, Eikon Therapeutics | Trial completion date: Mar 2024 --> Jul 2024 | Trial primary completion date: Mar 2024 --> Jul 2024
7 months ago
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2 (Interleukin 2) • TNFRSF9 (TNF Receptor Superfamily Member 9)
|
Tecentriq (atezolizumab) • EIK1001
9ms
A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=70, Recruiting, Eikon Therapeutics | Not yet recruiting --> Recruiting
9 months ago
Enrollment open • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • EIK1001
9ms
BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab (clinicaltrials.gov)
P1, N=40, Active, not recruiting, Eikon Therapeutics | Trial primary completion date: Dec 2023 --> Mar 2024
9 months ago
Trial primary completion date • Combination therapy • Metastases
|
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2 (Interleukin 2) • TNFRSF9 (TNF Receptor Superfamily Member 9)
|
Tecentriq (atezolizumab) • EIK1001
9ms
BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab (clinicaltrials.gov)
P1, N=50, Active, not recruiting, Eikon Therapeutics | Trial primary completion date: Dec 2023 --> Mar 2024
9 months ago
Trial primary completion date • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • EIK1001
9ms
A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=70, Not yet recruiting, Eikon Therapeutics
9 months ago
New P2 trial • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • EIK1001
over1year
BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab (clinicaltrials.gov)
P1, N=40, Active, not recruiting, Eikon Therapeutics | Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
over 1 year ago
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2 (Interleukin 2) • TNFRSF9 (TNF Receptor Superfamily Member 9)
|
Tecentriq (atezolizumab) • EIK1001
over1year
BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab (clinicaltrials.gov)
P1, N=50, Active, not recruiting, Eikon Therapeutics | Trial completion date: Dec 2022 --> Mar 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
over 1 year ago
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • EIK1001
over1year
BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors (clinicaltrials.gov)
P2, N=1, Completed, Eikon Therapeutics | Active, not recruiting --> Completed | N=100 --> 1 | Trial completion date: Jan 2023 --> May 2023 | Trial primary completion date: Jul 2022 --> Apr 2023
over 1 year ago
Trial completion • Enrollment change • Trial completion date • Trial primary completion date • IO biomarker • Metastases
|
EIK1001
over2years
BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab (clinicaltrials.gov)
P1, N=40, Active, not recruiting, Birdie Biopharmaceuticals HK Limited | Trial primary completion date: Jul 2022 --> Dec 2022
over 2 years ago
Trial primary completion date • Combination therapy
|
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2 (Interleukin 2) • TNFRSF9 (TNF Receptor Superfamily Member 9)
|
Tecentriq (atezolizumab) • EIK1001
over2years
BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab (clinicaltrials.gov)
P1, N=40, Active, not recruiting, Birdie Biopharmaceuticals HK Limited | Trial primary completion date: Jan 2022 --> Jul 2022
over 2 years ago
Trial primary completion date • Combination therapy
|
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2 (Interleukin 2) • TNFRSF9 (TNF Receptor Superfamily Member 9)
|
Tecentriq (atezolizumab) • EIK1001
3years
BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab (clinicaltrials.gov)
P1, N=40, Active, not recruiting, Birdie Biopharmaceuticals HK Limited | Recruiting --> Active, not recruiting
3 years ago
Clinical • Enrollment closed • Combination therapy
|
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2 (Interleukin 2) • TNFRSF9 (TNF Receptor Superfamily Member 9)
|
Tecentriq (atezolizumab) • EIK1001
over3years
BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab (clinicaltrials.gov)
P1, N=50, Recruiting, Birdie Biopharmaceuticals HK Limited | Trial completion date: Jan 2022 --> Dec 2022 | Trial primary completion date: Jul 2021 --> Jan 2022
over 3 years ago
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2 (Interleukin 2) • TNFRSF9 (TNF Receptor Superfamily Member 9)
|
Tecentriq (atezolizumab) • EIK1001
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login